美国癌症研究协会（AACR）2026年年会将于4月19日至22日在加州圣地亚哥举行。作为全球肿瘤研究领域的顶级盛会，本届年会将汇聚顶尖科学家，共同探讨癌症研究的前沿进展。

本届年会的举办地正是AC米兰中文官方网站生物北美总部所在地。依托于全新扩建的现代化研发园区，AC米兰中文官方网站生物已建立起符合国际标准的实验设施与快速响应体系，致力于为全球科研伙伴提供从基因工程动物模型到临床前研发的全链条支持。

此次AACR年会来到“AC米兰中文官方网站的家门口”，我们倍感珍惜。期待借此平台，与全球专家学者及合作伙伴深入交流、碰撞思想，共同探索科学创新的更多可能。

海报研究成果亮点抢先看

今年，AC米兰中文官方网站生物在AACR的海报展示规模进一步扩大，共有16项研究成果将通过海报形式呈现，涵盖肿瘤转移模型、人源化与免疫重建小鼠平台、CAR-T与T细胞衔接器（TCEs）、双特异性抗体、检查点抑制剂、癌症疫苗、治疗耐药以及癌症恶病质等前沿方向，全面展现我们在临床前肿瘤研究领域的广度与创新实力。这些研究成果将通过学术海报形式进行展示（以下为美国太平洋时间发布安排）：

Monday, April 20, 2026

09:00 AM - 12:00 PM 丨Section 27丨Board 12

Poster #2114: Murinemodels of bone and brain metastasis for preclinical cancer research 用于临床前癌症研究的骨与脑转移小鼠模型

09:00 AM - 12:00 PM丨Section 29丨Board 16

Poster #2165: An integrated preclinical platform for comprehensive evaluation of T-Cell engagers 用于全面评估T细胞衔接剂的一体化临床前平台

09:00 AM - 12:00 PM丨Section 29丨Board 17

Poster #2166: Robust in vivo CAR-T efficacy evaluation in a PBMC-reconstituted NCG-MHC-dKO model with delayed GVHD 在延迟GVHD的PBMC重建NCG-MHC双敲除模型中稳健评估CAR-T的体内疗效

09:00 AM - 12:00 PM丨Section 29丨Board 18

Poster #2167: A novel humanized mouse model for preclinical assessment of anti-CD47 and anti-SIRPΑtherapeutics 一种用于抗CD47及抗SIRPα疗法临床前评估的新型人源化小鼠模型

02:00 PM - 05:00 PM丨Section 27丨Board 18

Poster #3388: One-stop solution for preclinical evaluation of bispecific T-cell engagers targeting STEAP1 靶向STEAP1的双特异性T细胞衔接剂临床前评估一站式解决方案

02:00 PM - 05:00 PM丨Section 27丨Board 19

Poster #3389: Preclinical models for evaluating bispecific antibodies targeting PD-1 and VEGF 用于评估靶向PD-1和VEGF的双特异性抗体的临床前模型

02:00 PM - 05:00 PM丨Section 27丨Board 20

Poster #3390: Enhanced human immune system engraftment in a novel triple-engineered NCG-hIL6-mTSLP-mFlt3-KO mouse model 新型三重工程化NCG-hIL6-mTSLP-mFlt3-KO小鼠模型中增强的人免疫系统植入

02:00 PM - 05:00 PM丨Section 27丨Board 21

Poster #3391: The humanized FcRn mouse model: A superior platform for predicting human PK of therapeutic antibodies 人源化FcRn小鼠模型：一个用于预测治疗性抗体人体药代动力学的优越平台

02:00 PM - 05:00 PM丨Section 27丨Board 22

Poster #3392: Development of novel NCG-hIL15 and hIL-2 mouse models for preclinical assessment of human NK cell function 用于临床前评估人自然杀伤细胞功能的新型NCG-hIL15和hIL-2小鼠模型的开发

Tuesday, April 21, 2026

09:00 AM - 12:00 PM丨Section 10丨Board 22

Poster #4382: Bridging in vitro screening to in vivo efficacy for cancer vaccines 连接癌症疫苗体外筛选与体内疗效的桥梁

02:00 PM - 05:00 PM丨Section 17丨Board 28

Poster #5859: Novel T cell engager targeting CD3 and CDH17 for the treatment of solid tumors 一种靶向CD3和CDH17用于治疗实体瘤的新型T细胞衔接剂

02:00 PM - 05:00 PM丨Section 26丨Board 22

Poster #6076: Preclinical models of cancer cachexia: Bridging the gap to clinical applications 癌症恶病质的临床前模型：搭建通向临床应用的桥梁

Wednesday, April 22, 2026

09:00 AM - 12:00 PM丨Section 30丨Board 10

Poster #7492: Preclinical osimertinib-resistant mouse models for advancing third-generation EGFR-TKI drug development 用于推进第三代EGFR-TKI药物开发的奥希替尼耐药小鼠临床前模型

09:00 AM - 12:00 PM丨Section 30丨Board 11

Poster #7493: Novel preclinical models for evaluating checkpoint inhibitor resistance 用于评估检查点抑制剂耐药的新型临床前模型

09:00 AM - 12:00 PM丨Section 30丨Board 12

Poster #7494: Development of enhanced enhertu-resistant HER2-positive breast cancer models for ADC resistance research 用于ADC耐药研究的增强型Enhertu（德曲妥珠单抗）耐药HER2阳性乳腺癌模型的开发

09:00 AM - 12:00 PM丨Section 30丨Board 13

Poster #7495: Modeling of de novo and experimentally induced acquired resistance to trastuzumab deruxtecan in HER2-positive patient-derived xenografts 在HER2阳性患者来源异种移植模型中模拟曲妥珠单抗德鲁替康的原发性和实验诱导获得性耐药

以上时间均为美国圣地亚哥当地时间。

大会期间，AC米兰中文官方网站生物（GemPharmatech）在现场设置展台（#3250展位），为新老朋友提供交流的场所。

相约圣地亚哥，共话肿瘤新未来

我们诚挚邀请您莅临AACR 2026 #3250展位，与我们的科学家团队面对面交流，探讨您的研究计划与药物开发需求。

为更高效地与您沟通，我们特别开放一对一科学家会谈预约。您可扫描下方二维码，提前锁定与我们的专家深入交流的时间，获取量身定制的临床前研究方案建议，让这次AACR之行收获满满。

从早期发现到临床前验证，AC米兰中文官方网站生物提供一站式临床前CRO一体化解决方案，凭借深厚的转化医学经验，助您加速抗癌药物的研发进程。期待四月在圣地亚哥与您共话肿瘤研究新机遇！

The American Association for Cancer Research (AACR) Annual Meeting 2026 is set to take place from April 19 to 22 in San Diego, California. As a premier global gathering in the field of oncology research, this year's meeting will bring together leading scientists to explore the latest frontiers and advancements in cancer research.

The venue for this year's annual conference is precisely where GemPharmatech's North American headquarters is located. Supported by the newly expanded, modern R&D campus, GemPharmatech has established internationally compliant laboratory facilities and a rapid-response system, dedicated to providing global research partners with end-to-end support—from genetically engineered animal models to preclinical R&D.

With AACR 2026 being held, quite literally, on our doorstep, we treasure this opportunity. We look forward to leveraging this platform for in-depth exchanges and stimulating discussions with experts, scholars, and partners from around the world, jointly exploring greater possibilities for scientific innovation.

Preview of Poster Highlights

This year, GemPharmatech significantly expands its presence at AACR with a total of 16 research posters to be presented. Our work spans cutting-edge areas including tumor metastasis models, humanized and immune-reconstituted mouse platforms, CAR-T and T-cell engagers (TCEs), bispecific antibodies, checkpoint inhibitors, cancer vaccines, therapy resistance, and cancer cachexia. This diverse portfolio comprehensively demonstrates the breadth and innovative strength of our capabilities in preclinical oncology research. The research findings will be presented in academic poster sessions according to the following schedule (all times in Pacific Time):

Monday, April 20, 2026

09:00 AM - 12:00 PM 丨Section 27丨Board 12

Poster #2114: Murinemodels of bone and brain metastasis for preclinical cancer research 

09:00 AM - 12:00 PM丨Section 29丨Board 16

Poster #2165: An integrated preclinical platform for comprehensive evaluation of T-Cell engagers

09:00 AM - 12:00 PM丨Section 29丨Board 17

Poster #2166: Robust in vivo CAR-T efficacy evaluation in a PBMC-reconstituted NCG-MHC-dKO model with delayed GVHD 

09:00 AM - 12:00 PM丨Section 29丨Board 18

Poster #2167: A novel humanized mouse model for preclinical assessment of anti-CD47 and anti-SIRPΑtherapeutics 

02:00 PM - 05:00 PM丨Section 27丨Board 18

Poster #3388: One-stop solution for preclinical evaluation of bispecific T-cell engagers targeting STEAP1 

02:00 PM - 05:00 PM丨Section 27丨Board 19

Poster #3389: Preclinical models for evaluating bispecific antibodies targeting PD-1 and VEGF 

02:00 PM - 05:00 PM丨Section 27丨Board 20

Poster #3390: Enhanced human immune system engraftment in a novel triple-engineered NCG-hIL6-mTSLP-mFlt3-KO mouse model 

02:00 PM - 05:00 PM丨Section 27丨Board 21

Poster #3391: The humanized FcRn mouse model: A superior platform for predicting human PK of therapeutic antibodies 

02:00 PM - 05:00 PM丨Section 27丨Board 22

Poster #3392: Development of novel NCG-hIL15 and hIL-2 mouse models for preclinical assessment of human NK cell function 

Tuesday, April 21, 2026

09:00 AM - 12:00 PM丨Section 10丨Board 22

Poster #4382: Bridging in vitro screening to in vivo efficacy for cancer vaccines

02:00 PM - 05:00 PM丨Section 17丨Board 28

Poster #5859: Novel T cell engager targeting CD3 and CDH17 for the treatment of solid tumors 

02:00 PM - 05:00 PM丨Section 26丨Board 22

Poster #6076: Preclinical models of cancer cachexia: Bridging the gap to clinical applications 

Wednesday, April 22, 2026

09:00 AM - 12:00 PM丨Section 30丨Board 10

Poster #7492: Preclinical osimertinib-resistant mouse models for advancing third-generation EGFR-TKI drug development 

09:00 AM - 12:00 PM丨Section 30丨Board 11

Poster #7493: Novel preclinical models for evaluating checkpoint inhibitor resistance

09:00 AM - 12:00 PM丨Section 30丨Board 12

Poster #7494: Development of enhanced enhertu-resistant HER2-positive breast cancer models for ADC resistance research 

09:00 AM - 12:00 PM丨Section 30丨Board 13

Poster #7495: Modeling of de novo and experimentally induced acquired resistance to trastuzumab deruxtecan in HER2-positive patient-derived xenografts 

All times listed are in San Diego Local Time (Pacific Time).

During the conference, GemPharmatech will have a booth (Booth #3250) on site, serving as a hub for connecting with both longstanding and new friends.

Meet Us in San Diego

We warmly welcome you to visit us at Booth #3250 at AACR 2026 for face-to-face discussions with our scientific team about your research plans and drug development needs.

To facilitate efficient communication, we are offering one-on-one meetings with our scientists by appointment. Scan the QR code below to secure a dedicated time slot for an in-depth conversation with our experts. Receive tailored preclinical research proposals and make the most of your AACR 2026 experience.

GemPharmatech provides an integrated, one-stop preclinical CRO solution spanning from early discovery to preclinical validation. Leveraging our extensive translational medicine expertise, we are committed to accelerating the development of your anti-cancer drug pipeline. We look forward to discussing new opportunities in oncology research with you this April in San Diego!